InventisBio is a clinical stage biotech company dedicated to the research and development of innovative small molecule drugs.
InventisBio focuses on discovery and development of novel therapeutics in the areas of oncology and metabolic diseases to address unmet medical needs.
InventisBio was co-founded in 2013 by Dr. Yaolin Wang and other senior scientists. The company is headquartered in Shanghai, Shanghai, China, with an office in New Jersey.
InventisBio's product pipeline includes lung cancer, breast cancer, tumor immunity and gout, etc. The company is also actively developing drugs for other tumor and immune tumor targets.
InventisBio currently has four self-developed Class 1 new drugs, which are undergoing clinical Phase I and Phase II trials in China and the United States. The company’s philosophy is to exert the spirit of artisans in the discovery, development and delivery of high-quality and innovative therapies that benefit patients.
InventisBio is backed by Qiming Venture Partners, GL Ventures, Lilly Asia Venture, OrbiMed Asia, Pudong Innotek, Janchor, AIHC Capital, Matrix Partner China and others. The company raised $147M in Series D round on Oct 28, 2020. This brings InventisBio's total funding to $246.5M to date.